One of those conditions is sepsis. More patients die from sepsis than AIDS, prostate cancer and breast cancer combined. Early diagnosis is essential to fight conditions like sepsis, but biochemical limitations mean that patients often get caught too late.
Dascena develops algorithms as a new category of diagnostics to catch patients earlier when they can be effectively treated.
Our founder, Ritankar Das, began developing algorithms to help diagnose complex clinical conditions while a PhD student at the University of Cambridge. His mentor, Dr. P. Roy Vagelos, encouraged him to start a company in order to bring these life-saving algorithms to patients, and became our first investor. Subsequently, the company received four grants from the National Institutes of Health (NIH) to develop the technology and perform clinical trials. Today, our algorithms are used by over 50,000 clinicians and helps save thousands of lives.
Founder, Chief Executive Officer
Ritankar Das founded Dascena at the age of 19, while a PhD student and Gates scholar at the University of Cambridge. Ritankar has published over twenty peer-reviewed publications, and is the youngest principal investigator to receive research funding from the National Institutes of Health. He holds an MSc in biomedical engineering from Oxford University as well as a BS in bioengineering and a BS in chemical biology from the University of California, Berkeley, where he received the University Medal.
Director, Clinical Development
Christopher W. Barton oversees clinical development at Dascena. Prior to joining Dascena, Chris was the Chief of Service and Vice Chair at the Department of Emergency Medicine at the University of California, San Francisco (UCSF). Chris served on the UCSF faculty for twenty-three years. Chris received his MD from the University of California, San Francisco, and completed healthcare management executive education at the Harvard Business School.
Director, Scientific Communications
Jana L. Hoffman oversees scientific communications at Dascena. Jana joined Dascena in 2015 from Catalyst Biosciences, where she held roles of increasing responsibility on the scientific team. Prior to Catalyst Biosciences, she was a postdoc in the Kuo lab at Stanford, where she discovered a previously unknown function of the vascular endothelial growth factor (VEGF) as a repressor of hepatic erythropoetin expression. Jana holds a PhD in biophysical chemistry from the University of California, Berkeley and a BA in chemistry from Princeton University.
Director, Sales & Marketing
Jonathan Roberts leads the sales and marketing teams at Dascena. Jonathan spearheaded the national go-to-market efforts for Dascena’s flagship sepsis product, leading to adoption at hospitals across 21 states. Prior to Dascena, Jonathan held engineering management and sales leadership roles. In his free time, Jonathan enjoys mountaineering, rock climbing, and backpacking in the Sierras.
Director, Science & Technology
Joe Slote holds an MSc in Mathematics and Foundations of Computer Science from the University of Oxford and a Bachelors in Mathematics from Carleton College. After completing numerous robotics and software development projects at an early age, Joe has dedicated his career to the development of advanced mathematical approaches to engineering problems. When he is not architecting software or developing machine learning algorithms, Joe advocates for humane technology and effective altruism.